

Global use of GPHF-Minilabs for the detection of falsified and substandard quality medicines

Africa	
Benin	1
Cape Verde	1
Central African Republic	1
Djibouti	1
Gabun	1
Guinea-Equatorial	1
Niger	1
Swaziland	1
Botswana	2
Congo PR	2
Gambia	2
Ivory Coast	2
Lesotho	2
Namibia	2
Burkina Faso	3
Guinea-Bissau	3
Sudan	3
Togo	3
Eritrea	4
Zimbabwe	4
South Sudan	5
Guinea-Conakry	6
Somalia	6
Asia	
Malawi	7
Liberia	8
Burundi	9
Sierra Leone	10
Rwanda	12
Uganda	12
Zambia	12
Mali	13
Senegal	13
Cameroon	19
Mozambique	19
Kenya	20
Angola	22
Madagascar	24
Ethiopia	25
Congo DR	31
Ghana	31
Tanzania	45
Nigeria	59
448	214


Bangladesh	1
Georgia	1
Maldives	1
Sri Lanka	1
Tadzhikistan	1
Uzbekistan	1
West Bank & Gaza	1
Bhutan	2
Kyrgyztan	3
Nepal	3
Kazakhstan	5
Pakistan	12
India	15
Thailand	16
Afghanistan	17
Cambodia	19
Myanmar	26
Laos	27
Vietnam	62
214	61

America	
Belize	1
Grenada	1
Guatemala	1
St. Lucia	1
Virgin Islands (brit.)	1
Brazil	2
Nicaragua	2
Surinam	2
Venezuela	3
Ecuador	4
Bolivia	5
Peru	6
Guyana	6
Haiti	7
USA*	8
Colombia	11
61	25

Pacific	
Fiji Islands	1
Samoa	1
Timor Leste	1
Australia*	2
Taiwan*	3
China*	4
Papua New Guinea	9
Philippines	14
Indonesia	19
54	25

Europe	
Belgium*	1
Italy*	1
Netherlands*	1
Norway*	1
Spain*	1
Great Britain*	2
Switzerland*	2
Germany*	7
Russia*	9
25	802

1
2-3
4-9
10-19
≥ 20



The GPHF-Minilab™

A mini-laboratory developed by the Global Pharma Health Fund (GPHF) to boost the medicines testing capacity at healthcare providers in developing countries. Focus on priority essential medicines, for example anti-infectives. Non-sophisticated, affordable and fit for use in the field. Supplied more than 800 times to 95 countries already. Minilabs save lives. For more, go to www.gphf.org.



A charitable organisation maintained exclusively by Merck

* For training and demonstration purposes only | Latest update December 2016